7OFI image
Entry Detail
PDB ID:
7OFI
Title:
Ligand complex of RORg LBD
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-05-05
Release Date:
2022-03-16
Method Details:
Experimental Method:
Resolution:
1.95 Å
R-Value Free:
0.22
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 41 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Nuclear receptor ROR-gamma
Chain IDs:A
Chain Length:266
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Nuclear receptor coactivator 2
Chain IDs:B (auth: C)
Chain Length:18
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.
J.Med.Chem. 64 13807 13829 (2021)
PMID: 34464130 DOI: 10.1021/acs.jmedchem.1c01197

Abstact

Inverse agonists of the nuclear receptor RORC2 have been widely pursued as a potential treatment for a variety of autoimmune diseases. We have discovered a novel series of isoindoline-based inverse agonists of the nuclear receptor RORC2, derived from our recently disclosed RORC2 inverse agonist 2. Extensive structure-activity relationship (SAR) studies resulted in AZD0284 (20), which combined potent inhibition of IL-17A secretion from primary human TH17 cells with excellent metabolic stability and good PK in preclinical species. In two preclinical in vivo studies, compound 20 reduced thymocyte numbers in mice and showed dose-dependent reduction of IL-17A containing γδ-T cells and of IL-17A and IL-22 RNA in the imiquimod induced inflammation model. Based on these data and a favorable safety profile, 20 was progressed to phase 1 clinical studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures